Emerging Non-Clinical Biostatistics in Biopharmaceutical Development and Manufacturing
The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should be based upon a thorough understanding of both the product and the manufacturing process. This state-of-the-art book provides a single source of information on emerging statistical approaches to QbD and risk-based pharmaceutical development. A comprehensive resource, it combines in-depth explanations of advanced statistical methods with real-life case studies that illustrate practical applications of these methods in QbD implementation.
CHF 56.75
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
Produktdetails
- ISBN: 978-1-4987-0416-8
- EAN: 9781498704168
- Produktnummer: 21955685
- Verlag: Taylor & Francis Ltd.
- Sprache: Englisch
- Erscheinungsjahr: 2016
- Seitenangabe: 386 S.
- Plattform: PDF
- Masse: 7'639 KB
- Abbildungen: 30 schwarz-weiße Abbildungen
Über den Autor
Harry Yang, Ph.D., is senior director and head of the Non-Clinical Biostatistics Group at MedImmune, the global biologics arm of AstraZeneca headquartered in Gaithersburg, Maryland.
23 weitere Werke von Harry Yang:
Emerging Non-Clinical Biostatistics in Biopharmaceutical Development and Manufacturing
Ebook (EPUB Format)
CHF 56.10
Bewertungen
Anmelden